AA
CAPR icon

ALPS Advisors’s Capricor Therapeutics CAPR Stock Holding History

ALPS Advisors’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-22,112
Closed -$159K – 1023
2025
Q3 		$159K Sell
22,112
-2,559
-10% -$18.8K ﹤0.01% 1011
2025
Q2 		$245K Sell
24,671
-8,559
-26% -$90.4K ﹤0.01% 994
2025
Q1 		$315K Sell
33,230
-3,540
-10% -$49.1K ﹤0.01% 887
2024
Q4 		$507K Buy
+36,770
New +$644K ﹤0.01% 601

Other funds holding CAPR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ALPS Advisors's CAPR Position: Q4 2025 in Review

ALPS Advisors sold out of Capricor Therapeutics (CAPR) in Q4 2025, closing a stake of 22,112 shares — an estimated $159K sold.

ALPS Advisors first reported a position in CAPR in Q4 2024 and held it in 4 quarters. The position peaked at $507K in Q4 2024. 132 funds tracked by Wall St. Rank hold CAPR as of Q4 2025.

  • ALPS Advisors reported no remaining Capricor Therapeutics position as of Q4 2025 after selling out during the quarter.
  • ALPS Advisors sold 22,112 Capricor Therapeutics shares in Q4 2025, an estimated $159K.
  • ALPS Advisors first reported a position in Capricor Therapeutics in Q4 2024 and held it in 4 quarters.
  • ALPS Advisors's Capricor Therapeutics position peaked at $507K in Q4 2024.
  • 132 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q4 2025.

Based on ALPS Advisors's 13F filing for Q4 2025, filed 12 Feb 2026.